Leggett action continues
16 September, 2008 by Dylan Bushell-EmblingLitigation against former Agenix CEO Neil Leggett to continue next week
Pharmaxis banks
16 September, 2008 by Dylan Bushell-EmblingPharmaxis in strong cash position for FY09
BioDiem at Portugal flu conference
16 September, 2008 by Dylan Bushell-EmblingBioDiem presents LAIV research at influenza conference
Millipore product guide to antibodies
16 September, 2008 by External Press Release AuthorMillipore announces the availability of its new Antibodies and Kits Product Guide, a comprehensive resource for navigating Millipore’s antibodies, immunoassay products and recombinant proteins for over 2500 unique targets.
Vaccines and the world
12 September, 2008 by Staff WritersThe World Vaccines Congress is coming to Sydney next month
BioLayer assays Prince of Wales
10 September, 2008 by Dylan Bushell-EmblingBioLayer to partner with Prince of Wales to develop Parkinson's detection tools
Venturous Australia: innovation review released
09 September, 2008 by Kate McDonaldR&D tax credits, pre-seed grants, full funding of university research recommended
Peplin into Phase III
09 September, 2008 by Dylan Bushell-EmblingPeplin to conduct Phase III trial of PEP005 under special protocol assessment
Coats on for Starpharma
09 September, 2008 by Dylan Bushell-EmblingStarpharma sells VivaGel condom marketing rights to Durex in potential $100m deal
ASCC board squabble blows up
06 September, 2008 by Kate McDonaldStakeholders take over control of stem cell centre
Board quits stem cell centre
05 September, 2008 by Kate McDonaldThe board of the Australian Stem Cell Centre (ASCC) is set to resign
Spinifex gets cash for pain
04 September, 2008 by Kate McDonaldInvestors inject $12 million in private biotech Spinifex
Fluorotechnics to list on ASX
04 September, 2008 by Dylan Bushell-Embling and Kate McDonaldFluorescence specialist Fluorotechnics takes plunge with an IPO
Cytopia begins Phase II
04 September, 2008 by Dylan Bushell-EmblingCytopia in Phase II trials of its vascular disrupting agent CYT997 in brain cancer
Anadis to commercialise BioGard
04 September, 2008 by Dylan Bushell-EmblingBioGard is a supplemented bovine colostrum powder for immune system health
